Trial Profile
An Open-label, Parallel-group, Randomized, Multicenter Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Jul 2022
Price :
$35
*
At a glance
- Drugs Vilaprisan (Primary)
- Indications Uterine leiomyoma
- Focus Adverse reactions; Registrational
- Acronyms ASTEROID 8
- Sponsors Bayer
- 06 Jul 2022 Status changed from completed to discontinued.
- 09 Dec 2021 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI183908).
- 15 Jul 2021 Status changed from active, no longer recruiting to completed.